Sign In
22 Oct 2012 13:52
For immediate release 22 October 2012
ABCAM PLC
("Abcam" or the "Company")
Result of AGM
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, announces that all resolutions put to its Annual General Meeting held earlier today were duly passed.
At the meeting, Michael Redmond, Abcam's Chairman, thanked Prof Tony Kouzarides, a co-founder of the Company and a Non-Executive Director for 14 years, who, as previously announced, stepped down from the Board at the close of the Annual General Meeting.
Michael Redmond, Abcam's Chairman, said: "I would like to thank Tony, on behalf of everyone at Abcam, for the immense contribution he has made, playing a vital role in the Company's success. We wish him well for the future."
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer Jeff Iliffe, Chief Financial Officer www.abcam.com | |
Numis Securities - Nominated Advisor and Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Advisor James Black - Corporate Broking | |
Peel Hunt LLP - Joint Broker | + 44 (0) 207 418 8900 |
Andy Crossley - Corporate Broking | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 130 countries. Abcam employs over 600 staff across its eight operating companies.
Abcam now has an online catalogue of more than 98,000 products sourced from more than 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website, www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science reagents company.
Follow the stocks
